AEGiS-NIAID: NIAID Investigating New Treatment for Hepatitis C in Co-Infected Patients

Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.

NIAID Investigating New Treatment for Hepatitis C in Co-Infected Patients

NIAID Online Update - September 23, 2009

The Centers for Disease Control and Prevention estimates that approximately 25 percent of HIV-infected people in the United States are also infected with the hepatitis C virus (HCV). HCV infection is a major cause of liver damage and progresses more rapidly in HIV-infected people. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), are enrolling volunteers for a clinical trial to evaluate a new treatment that may suppress the HCV virus in HIV/HCV co-infected patients.

The clinical trial is being conducted at the NIH in Bethesda, MD.

For more information about this clinical trial, see http://www3.niaid.nih.gov/Volunteer/HIVandInfectious/ViralHepatit isStudies/albin.htm.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
090923
NI090903

Published 2009 - National Institute of Allergy and Infectious Diseases . All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .